Detalhe da pesquisa
1.
The long-term efficacy and safety of nilotinib in pediatric patients with CML: a 5-year update of the DIALOG study.
Blood Adv
; 7(23): 7279-7289, 2023 12 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37738125
2.
A phase 2 study of nilotinib in pediatric patients with CML: long-term update on growth retardation and safety.
Blood Adv
; 5(14): 2925-2934, 2021 07 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-34309636
3.
Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial.
Leukemia
; 35(5): 1344-1355, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33707652
4.
Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis.
Leukemia
; 35(2): 440-453, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33414482
5.
Correction to: Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis.
Leukemia
; 35(7): 2142-2143, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-34108614